This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Klinikum Der Universitat Munchen, Université De Caen Basse Normandie. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Certainly! Here is an article about inventor Luis Felipe Romero Saavedra:
Title: Innovator Spotlight - Luis Felipe Romero Saavedra
Introduction:
Luis Felipe Romero Saavedra, a notable inventor based in Munich, Germany, has made significant contributions to the field of medicine through his innovative work in developing polypeptides for vaccination and therapeutic antibody generation.
Latest Patents:
Luis Felipe Romero Saavedra holds one patent for "Polypeptides derived from and their use for vaccination and the generation of therapeutic antibodies." This patent describes a medicament for treating or preventing bacterial infections using specific polypeptides that induce opsonic antibodies in patients in need.
Career Highlights:
Having worked at Klinikum Der Universität München and Universite De Caen-Basse Normandie, Luis Felipe Romero Saavedra has gained valuable experience in the medical research field. His dedication to developing novel medical solutions has led to the successful patenting of his innovative polypeptide-based approach.
Collaborations:
Throughout his career, Luis Felipe Romero Saavedra has collaborated with esteemed professionals in the field. Notable coworkers include Johannes Hübner and Axel Hartke, who have worked alongside him in advancing the research and development of polypeptide-based vaccines and therapeutic antibodies.
Conclusion:
In conclusion, Luis Felipe Romero Saavedra's groundbreaking work in the development of polypeptides for vaccination and therapeutic antibody generation showcases his commitment to pushing the boundaries of medical innovation. His contributions have the potential to revolutionize the treatment and prevention of bacterial infections, paving the way for a healthier future for patients worldwide.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile